Analyst Consideration on: Abbott Laboratories (ABT)

07/21/2016 - Abbott Laboratories had its "overweight" rating reiterated by analysts at Barclays. Abbott Laboratories comprises about 7.6% of Old West Investment Management LLC's portfolio, making the stock its 2nd largest position. TIAA CREF Investment Management LLC now owns 11,557,232 shares of the healthcare product maker's stock worth $488,755,000 after buying an additional 1,385,598 shares in the last quarter. Ronna Sue Cohen boosted its position in Abbott Laboratories by 1.6% in the third quarter.

The Stock has Weekly volatility of 1.26% and monthly volatility of 1.13%. Pure Financial Advisors Inc. increased its stake in Abbott Laboratories by 0.4% in the third quarter. Northern Trust Corp boosted its position in shares of Abbott Laboratories by 9.4% in the third quarter.

On 17 March 2017, Huntington Bancshares Incorporated (NASDAQ:HBAN) shares moved to $13.73 after starting the day at $13.92. Burke & Herbert Bank & Trust Co. now owns 16,995 shares of the healthcare product maker's stock valued at $718,000 after buying an additional 921 shares during the last quarter.

Abbott Laboratories (NYSE:ABT) has price target of $48.1 for forthcoming year. The company has a market capitalization of $78.09 billion, a P/E ratio of 48.23 and a beta of 0.97. Looking at the stock's movement on the chart, Abbott Laboratories recorded a 52-week high of $45.84.

Moving toward other technical indicators, Abbott Laboratories (NYSE:ABT)is wondering in considerable region as it has 20 days moving average of -0.08% and struggles for 50 days moving average of buoyant run is 5.20%. For the current estimate trends of EPS, pool recommendation was $0.43 and for one month was $0.43. The firm earned $5.33 billion during the quarter, compared to analysts' expectations of $5.41 billion. Abbott Laboratories had a net margin of 6.71% and a return on equity of 15.74%. The business's revenue for the quarter was up 2.8% compared to the same quarter previous year. On average, equities analysts anticipate that Abbott Laboratories will post $2.45 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, May 15th. Perhaps, that suggests something about why 0.02% of the outstanding share supply is held by institutional investors. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.35%. The ex-dividend date of this dividend is Tuesday, April 11th. Abbott Laboratories's dividend payout ratio is now 113.98%.

Several Insider Transactions has been reported to the SEC. Zacks Investment Research upgraded Abbott Laboratories from a "hold" rating to a "buy" rating and set a $46.00 price objective for the company in a report on Tuesday, January 10th. Jefferies Group LLC reaffirmed a "buy" rating and set a $51.00 price objective on shares of Abbott Laboratories in a report on Friday, February 17th. TheStreet upgraded shares of Abbott Laboratories from a "c+" rating to a "b" rating in a research note on Wednesday, March 8th. Out of 0 brokerage recommendations, 0 gave a Strong Buy, 0 issued a Buy, 0 issued Hold, 0 rated Under-perform and 0 issued a Sell. They now have a United States dollars 55 price target on the stock. The company's stock has fell -14.79 percent in the past five year. The stock has been active on the tape, now trading at $45.19, up from yesterday's close by 0.47%. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance.

In the trailing 12 months period, return on assets ratio of the Company was 3.30% and return on equity ratio was 6.80% while its return on investment ratio was 6.70%. The disclosure for this purchase can be found here. A total of 12.28 million shares exchanged at hands and its average trading volume is standing at 8.82 million shares.